KEMİK TUTULUMU İLE METASTATİK KANSERİ TAKLİT EDEN PULMONER SARKOİDOZ OLGUSU

Yıl 2022, , 125 - 129, 25.01.2022

Ece Şahinoğlu , Ahmet Hamdi Ilgazlı

https://doi.org/10.26650/IUITFD.853034

Öz

Sarkoidoz etyolojisi bilinmeyen, özellikle akciğer ile lenf bezlerini, cildi, gözleri ve diğer organları tutabilen; fakat nadiren kemik ve kemik iliğini tutan bir hastalıktır. Otuz dokuz yaşında, iliak kemikte maligniteyi taklit eden lezyonu olan, biyopsi ile sarkoidoz olduğu kanıtlanan bir erkek hastayı sunduk. Lenfoma veya metastatik kanser ayırıcı tanısı yapmak son derece zordu. Hastaya akciğer ve iliak kemikten birçok biyopsi yapıldı. Hepsinin sonucu nonnekrotizan granulomatöz inflamasyon olarak raporlandı. Hastaya kortikosteroid tedavisi başlandı. Steroid tedavisine yeterli yanıt alınamayan hastanın steroid tedavisine metotreksat ilave edildi. Bunun sonrasında klinik ve radyolojik iyileşme kaydedildi. Bu olguda, maligniteyi benign bir hastalıktan ayırt edebilmek ve tanıyı doğrulamak için yeni biyopsilerle ytekrarlanan histopatolojik değerlendirmenin öneminin vurgulanması hedeflendi.

Anahtar Kelimeler

Sarkoidoz, ayırıcı tanı, malignite

PULMONARY SARCOIDOSIS WITH BONE INVOLVEMENT MIMICKING METASTATIC CANCER

Öz

Sarcoidosis is a disease of unknown etiology which can affect the lungs and lymph nodes, skin, eyes and other organs and, in rare cases, bones and bone marrow cells. We present a case of a 39-year-old male patient with an iliac bone involvement of sarcoidosis mimicking malignancy. Lymphoma and metastatic cancer proved a challenge to discard in differential diagnosis. He underwent multiple biopsies including tru-cut lung parenchyma and iliac bone biopsies. All of the biopsy specimens were reported as non-necrotising granulomatous inflammation. He underwent corticosteroid treatment. His response to the steroid treatment was insufficient so methotrexate was added to the corticosteroid therapy. Afterwards, clinical and radiological improvement was recorded. We aimed to highlight the utilization of taking new biopsies and histopathological re-evaluations in order to confirm the diagnosis and distinguish a benign disease from a malignant one.

Anahtar Kelimeler

sarcoidosis, differential diagnosis, malignancy

Kaynakça

• 1. Brincker H. The sarcoidosis-lymphoma syndrome. Br J Cancer 1986;54(3):467-73. [CrossRef]
• 2. Heinle R, Chang C. Diagnostic criteria for sarcoidosis. Autoimmunity Reviews 2014;13(4-5):383-7. [CrossRef]
• 3. James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. Ann N Y Acad Sci 1976;278:321-34. [CrossRef]
• 4. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160(2):736- 55.
• 5. Costabel U, Bonella F, Ohshimo S, Guzman J. Diagnostic modalities in sarcoidosis: BAL, EBUS, and PET. Semin Respir Crit Care Med 2010;31(4):404-8. [CrossRef]
• 6. Danila E, Norkūniene J, Jurgauskiene L, Malickaite R. Diagnostic role of BAL fluid CD4/CD8 ratio in different radiographic and clinical forms of pulmonary sarcoidosis. Clin Respir J 2009;3(4):214-21. [CrossRef]
• 7. Kantrow SP, Meyer KC, Kidd P, Raghu G. The CD4/CD8 ratio in BAL fluid is highly variable in sarcoidosis. Eur Respir J 1997;10(12):2716-21. [CrossRef]
• 8. Fernández-Ruiz M, Guerra-Vales JM, Castelbón-Fernández FJ, Llenas-García J, Rodríguez-Peralto JL, López-Lancho R, et al. Sarcoidosis presenting as an osteolytic skull lesion: a case report and review of literature on skull sarcoidosis. Clin Rheumatol 2007;26(10):1745-8. [CrossRef]